GlassScriptPhysician profile
Scott T Kawamoto
NPI 1245441583
$58,029.75
in general payments reported to CMS, 2019-2025
29 companies · $3,241 in 2025
The $3,241 reported for 2025 was more than what 79% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $3,610 · 2021: $2,955 · 2022: $1,881 · 2023: $3,145 · 2024: $3,687 · 2025: $3,241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,340 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,339.86 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $734.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $46,037.41 | 2019-2025 | Evenity, Otezla, Enbrel |
| Abbvie INC. | $2,591.33 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,877.23 | 2021-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $1,342.07 | 2019-2025 | Benlysta |
| Pfizer INC. | $1,112.16 | 2019-2025 | |
| Ucb, INC. | $1,001.23 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $991.28 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $815.17 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $240.79 | 2022-2024 | Lupkynis |
| Genzyme Corporation | $230.56 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $215.66 | 2020-2025 | Acthar |
| Insmed, INC. | $181.77 | 2019-2024 | Arikayce |
| Mallinckrodt Enterprises LLC | $164.80 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.31 | 2019-2023 | Cyltezo |
| Horizon Therapeutics Plc | $152.22 | 2019-2023 | Krystexxa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $144.05 | 2019-2023 | Tymlos |
| Janssen Biotech, INC. | $126.59 | 2019-2025 | Stelara, Tremfya, Simponi |
| Alexion Pharmaceuticals, INC. | $114.12 | 2021-2024 | Strensiq |
| Genentech USA, INC. | $112.49 | 2019-2025 | Gazyva, Actemra |
| Gilead Sciences, INC. | $85.82 | 2019 | |
| Ani Pharmaceuticals, INC. | $63.11 | 2025 | Purified Cortrophin Gel |
| Genentech, INC. | $49.95 | 2021 | |
| Kyowa Kirin, INC. | $49.51 | 2023-2024 | Crysvita |
| Bioventus LLC | $43.20 | 2019-2025 | Xcell |
| E.R. Squibb & Sons, L.L.C. | $41.81 | 2019-2024 | Orencia |
| Sobi, INC | $24.78 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $24.77 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $24.30 | 2023 | Uptravi, Opsumit |
| Ferring Pharmaceuticals INC. | $19.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Kawamoto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.